Major pharmaceutical deals finalized in October
The completion of two major deals involving pharmaceutical companies was announced this month. The deals shuffle around several vaccine and companion animal pharmaceutical lines, but the companies say veterinarians won’t see any changes right away.
New Pfizer Animal Health
Pfizer Inc. will add more than two dozen new companion animal pharmaceutical products to its inventory, as part of its approximately $68 billion acquisition of Wyeth and its subsidiary Fort Dodge Animal Health.
Pfizer now has the Lyme disease vaccine Lymevax, topical flea and tick control product Promeris, and anesthetic Ketaset. Pfizer will retain a total of 28 Fort Dodge over-the-counter and prescription companion animal products (See the full list below). Pfizer will also retain several of Fort Dodge’s devices: The balance of Fort Dodge’s companion animal products went to pharmaceutical company Boehringer Ingelheim under that company’s agreement with Pfizer, according to Pfizer Associate Marketing Manager Deirdre O’Brien.
In a company news release, Pfizer said that all current U.S. pricing, product distribution, programs and policies for Pfizer Animal Health products, including the acquired Fort Dodge products, will remain in place through 2009.
“We’re extremely proud to offer our customers even more best-in-class and innovative products,” said Clint Lewis, president of U.S. Operations for Pfizer Animal Health. “The products, services and expertise we are gaining strengthen what is already a robust U.S. portfolio and will enhance our leading position in the animal health marketplace.”
The completion of Pfizer’s acquisition of Wyeth opened the door for the Boehringer Ingelheim deal to go through.
Boehringer Ingelheim - Fort Dodge deal
Boehringer Ingelheim (BI) and its U.S. animal health division, Boehringer Ingelheim Vetmedica, Inc., announced last month that it had entered into an agreement with Pfizer to acquire certain assets of Fort Dodge Animal Health. The deal was completed on Oct. 26 for an undisclosed amount.
As part of the deal, BI said it will acquire the Duramune canine vaccine line, the Fel-O-Vax feline vaccine line, and the Rabvac line of rabies vaccines manufactured and sold in the U.S., Canada and Australia. Several pet and equine pharmaceutical products currently sold in the U.S. were also included in the deal, but details on these products were not disclosed. Products being acquired in Europe are still subject to approval by European anti-trust authorities, the company said.
BI said customers should not see many changes after the deal is complete.
“This agreement does not change any aspect of how Boehringer Ingelheim interacts with its customers,” said BI spokeswoman Amy Kunkel. “It is our goal to make the transition process as seamless as possible for our customers and any changes resulting from this integration would be communicated to our customers immediately.”
Fort Dodge products to be retained by Pfizer